Table 1.

Growth percent of compounds 3a–e and 8a–d (at conc. 10⁻⁵ M) against different cell lines.

Panel/Cell Line		3a	3b	3c	3d	3e	8a	8b	8c	8d
Leukemia	CCRF-CEM	20.15	59.23	103.65	116.03	77.39	7.77	49.02	58.83	48.46
	HL-60(TB)	8.41	72.97	120.12	118.34	97.61	3.67	17.11	50.76	46.34
	K-562	22.24	51.17	112.34	128.49	74.12	14.31	54.53	65.03	58.59
	MOLT-4	16.68	78.95	115.46	132.80	91.47	11.35	32.30	54.75	43.07
	RPMI-8226	24.80	41.03	127.65	133.56	80.48	9.83	37.81	74.17	62.22
	SR	38.87	51.66	108.54	103.66	70.59	11.99	53.27	60.88	45.35
Non-Small Cell Lung Cancer	A549/ATCC	35.96	20.00	76.74	138.85	32.30	2.64	12.65	43.90	28.88
	EKVX	29.59	11.57	120.17	161.32	32.49	7.32	21.69	41.82	31.03
	HOP-62	33.63	22.46	80.49	158.60	45.90	6.03	22.55	24.84	19.99
	HOP-92	0	0	78.49	109.79	4.51	3.02	11.28	40.36	28.25
	NCI-H226	48.81	33.73	51.50	26.96	35.15	5.88	13.23	24.77	21.36
	NCI-H23	69.39	68.04	134.07	132.12	90.37	2.21	21.82	44.16	39.27
	NCI-H322M	0.21	0	32.21	19.52	3.95	1.65	5.69	2.44	4.81
	NCI-H460	28.14	25.07	87.28	90.38	46.08	0	39.19	47.70	29.96
	NCI-H522	31.97	47.13	120.20	134.81	62.67	7.64	18.21	23.62	22.73
Colon Cancer	COLO 205	0	0	80.85	57.45	3.67	0	15.44	55.51	39.55
	HCC-2998	13.21	0	133.50	137.87	38.63	0	2.86	10.89	0
	HCT-116	39.13	44.14	132.42	150.92	109.10	8.46	63.36	72.90	59.89
	HCT-15	48.69	44.66	168.35	168.11	97.21	0	57.16	50.52	33.91
	HT29	8.23	0.35	73.95	50.97	0	5.99	26.49	69.86	50.14
	KM12	21.19	25.15	93.96	129.88	64.80	0	18.15	43.43	17.79
	SW-620	24.10	22.49	159.75	156.56	81.66	4.29	20.05	27.07	18.93
CNS Cancer	SF-268	32.26	41.37	91.21	110.65	54.82	15.04	19.26	37.67	29.00
	SF-295	12.21	5.24	30.80	69.03	20.44	9.26	14.92	54.00	36.89
	SF-539	7.45	12.52	198.29	194.41	94.83	0	4.73	22.07	18.69
	SNB-19	39.25	25.88	95.41	174.30	66.30	1.20	9.35	33.22	17.91
	SNB-75	63.66	66.13	194.63	198.23	110.40	20.65	27.60	46.73	41.79
	U251	17.35	29.29	99.78	181.45	67.40	8.65	42.13	46.10	26.06
Melanoma	LOX IMVI	37.84	64.25	180.28	183.86	99.49	4.55	39.20	40.06	22.40
	MALME-3M	169.26	94.48	188.59	187.38	164.33	0	0.23	23.30	14.64
	M14	95.86	80.70	193.88	193.47	121.83	0	13.94	24.45	14.96
	MDA-MB-435	172.49	185.53	193.49	197.05	193.24	0	7.06	32.55	24.57
	SK-MEL-2	24.77	22.73	117.29	140.56	50.50	0	0.55	14.41	21.90
	SK-MEL-28	7.59	8.64	135.36	181.24	59.83	0	8.15	27.78	18.01
	SK-MEL-5	60.33	48.69	198.49	196.93	177.60	3.12	44.92	110.14	83.18
	UACC-257	37.58	47.42	172.55	190.50	128.61	0	5.58	51.31	33.52
	UACC-62	29.18	33.59	136.03	154.04	112.39	5.12	34.09	47.31	46.24
Ovarian Cancer	IGROV1	51.23	46.96	120.49	139.81	65.42	0	12.89	18.70	19.70
	OVCAR-3	35.24	48.92	126.39	118.83	98.89	3.35	30.37	46.79	39.78
	OVCAR-4	30.63	52.34	196.31	198.41	59.51	10.84	29.10	66.51	59.08
	OVCAR-5	0	0	165.70	177.37	0	0	0	0	0
	OVCAR-8	37.77	53.68	94.40	182.60	96.21	2.18	11.63	34.51	22.47
	NCI/ADR-RES	29.79	35.70	112.75	122.75	82.21	0.82	8.21	32.84	28.33
	SK-OV-3	23.68	27.13	44.32	38.03	40.91	4.34	19.80	17.91	21.63
Renal Cancer	786-0	19.04	17.33	121.83	190.37	31.40	0.60	12.69	29.94	22.26
	A498	6.32	13.32	44.03	48.42	10.55	26.71	13.08	37.26	27.25
	ACHN	57.35	57.98	195.25	190.19	74.36	0	11.65	27.66	15.91
	CAKI-1	67.87	56.64	79.67	91.15	69.16	9.75	42.98	39.11	32.21
	RXF 393	29.32	39.72	126.32	187.24	46.32	0	13.75	25.92	26.73
	SN12C	29.81	38.18	196.64	191.17	69.12	7.24	19.77	25.74	18.58
	TK-10	−8.43	0	41.72	11.39	0	0	8.81	20.32	20.52
	UO-31	66.37	61.82	135.24	173.08	78.47	32.71	42.83	57.68	49.11
Prostate Cancer	PC-3	33.67	42.21	99.63	102.79	69.33	14.03	54.49	62.23	51.20
	DU-145	28.33	11.20	190.66	191.42	66.79	0	7.12	25.02	12.24
Breast Cancer	MCF7	54.39	59.97	162.80	163.07	88.50	16.30	35.02	64.10	47.06
	MDA-MB-231/ATCC	60.00	59.61	106.76	107.49	84.61	0	10.63	7.06	4.91
	HS 578T	21.13	27.78	109.43	108.98	53.83	15.85	21.79	41.31	38.71
	BT-549	32.10	22.75	199.09	197.40	62.82	7.56	17.13	46.06	39.07
	T-47D	28.91	64.88	103.21	119.84	79.61	11.05	46.29	79.21	75.60
	MDA-MB-468	0	20.05	130.08	133.70	67.59	0	32.25	60.86	56.41